Hyper-inflammation and complement in COVID-19

21Citations
Citations of this article
25Readers
Mendeley users who have this article in their library.

Abstract

COVID-19 is a complex disease manifesting in a broad severity spectrum and involving distinct organs and systems. Hyperinflammation, including complement over-activation, has a pivotal role in severe COVID-19 pathobiology, stimulating the inflammatory response, causing microangiopathy, platelet–neutrophil activation, and hypercoagulability. SARS-CoV-2 can directly activate the complement system by the classic, alternative, and lectin pathways, and infected cells can produce intracellular complement (the complesome). COVID-19 severity appears to be associated with the degree of complement activation, and it has been hypothesized that patients with COVID-19 may benefit from therapeutic complement inhibition. Different complement cascade molecules may be targeted with potential advantages and disadvantages. Which target(s) is the most effective and when is the best timing for intervention remain open questions. Early phase I and phase II clinical trials have shown promising but conflicting results, warranting phase III controlled randomized trials. Upstream complement inhibition appears to better and more effectively block hyperinflammation with potential clinical significance. Understanding how SARS-CoV-2 exploits the complement system can add precious information about the pathogenesis of other infections, inflammatory, and autoimmune diseases beyond COVID-19.

References Powered by Scopus

Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

17160Citations
N/AReaders
Get full text

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

5414Citations
N/AReaders
Get full text

Complement: A key system for immune surveillance and homeostasis

2896Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Endotheliopathy in Acute COVID-19 and Long COVID

27Citations
N/AReaders
Get full text

Complement dysregulation is a prevalent and therapeutically amenable feature of long COVID

17Citations
N/AReaders
Get full text

SARS-CoV-2 immunity in animal models

11Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Pires, B. G., & Calado, R. T. (2023, May 1). Hyper-inflammation and complement in COVID-19. American Journal of Hematology. John Wiley and Sons Inc. https://doi.org/10.1002/ajh.26746

Readers over time

‘23‘24‘25036912

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 4

67%

Researcher 2

33%

Readers' Discipline

Tooltip

Immunology and Microbiology 4

50%

Biochemistry, Genetics and Molecular Bi... 2

25%

Neuroscience 1

13%

Agricultural and Biological Sciences 1

13%

Save time finding and organizing research with Mendeley

Sign up for free
0